Condition: HER2 Expressing Solid Tumors · Sponsor: Advaxis, Inc.
This is a Phase 1b, multicenter, open-label, dose-escalation study designed to estimate the maximum tolerated dose (MTD) and determine the recommended Phase 2 dose (RP2D) of ADXS31-164. Once the RP2D has been selected, up to 4 expansion cohorts will be evaluated.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Not Yet Recruiting | Los Angeles, California, United States | — |
| Site | Aurora, Colorado, United States | — |
| Study site | Grand Rapids, Michigan, United States | — |
| Site | Charlotte, North Carolina, United States | — |
| Site | Philadelphia, Pennsylvania, United States | — |
| Study site | Dallas, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02386501